Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revance Therapeutics (NQ: RVNC ) 6.580 +0.010 (+0.15%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Revance Therapeutics < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022 May 03, 2022 From Revance Therapeutics, Inc. Via Business Wire NASDAQ: RVNC Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Revance Therapeutics, Inc. April 27, 2022 San Diego, CA -- (SBWIRE) -- 04/27/2022 -- An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares over possible breaches of fiduciary duty by... Via SBWire The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial April 22, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines April 21, 2022 Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for... Via Benzinga Earnings Scheduled For February 28, 2022 February 28, 2022 Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... Via Benzinga Revance Therapeutics Update February 06, 2022 Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options Via NewMediaWire Revance Therapeutics Update January 30, 2022 Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options Via NewMediaWire Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines April 21, 2022 From Revance Therapeutics, Inc. Via Business Wire The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight April 03, 2022 Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... Via Benzinga Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting March 28, 2022 From Revance Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Monday's Pre-Market Session March 21, 2022 Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million. Via Benzinga Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management March 21, 2022 From Revance Therapeutics, Inc. Via Business Wire Revance Therapeutics: Q4 Earnings Insights February 28, 2022 Revance Therapeutics (NASDAQ:RVNC) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... Via Benzinga Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022 February 22, 2022 From Revance Therapeutics, Inc. Via Business Wire Deadline Today Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm February 08, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm February 07, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal TUESDAY DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RVNC February 05, 2022 From Robbins Geller Rudman & Dowd LLP Via Business Wire Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Revance Therapeutics, Inc. (RVNC) Investors of Filing Deadline in Class Action Lawsuit February 05, 2022 From Kessler Topaz Meltzer & Check, LLP Via Business Wire Revance Therapeutics Class Action Reminder February 05, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire REVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the Firm February 04, 2022 From Bragar Eagel & Squire, P.C. Via Business Wire Deadline Tuesday Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm February 04, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) February 04, 2022 From The Law Offices of Frank R. Cruz Via Business Wire Revance Therapeutics Shareholder Notice February 03, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Deadline Tuesday Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm February 03, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal Revance Therapeutics Shareholder Alert February 02, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Tuesday Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm February 02, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal Revance Therapeutics Deadline Alert February 01, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire 7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm February 01, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal Upcoming Deadline Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm January 31, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal ROSEN, A LEADING LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action RVNC January 29, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.